ArticleGenes, chromosomes & cancer2010
Distinct MHC gene expression patterns during progression of melanoma.
Article in Genes, chromosomes & cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 38 citations in OpenAlex.
- Article
- The Transcriptional Landscape ofInternational journal of molecular sciences · 2022Article
- Genomic landscape of the immunogenicity regulation in skin melanomas with diverse tumor mutation burden.Frontiers in immunology · 2022Article
- Article
- The Role of Extracellular Matrix Remodeling in Skin Tumor Progression and Therapeutic Resistance.Frontiers in molecular biosciences · 2022Review
- Distinct Molecular Mechanisms of Altered HLA Class II Expression in Malignant Melanoma.Cancers · 2021Article
- Chimeric Antigen Receptor (CAR) T Cell Therapy for Metastatic Melanoma: Challenges and Road Ahead.Cells · 2021Review
- A Multi-Omics Analysis of Metastatic Melanoma Identifies a Germinal Center-Like Tumor Microenvironment in HLA-DR-Positive Tumor Areas.Frontiers in oncology · 2021Article
- Expressions of HLA Class II Genes in Cutaneous Melanoma Were Associated with Clinical Outcome: Bioinformatics Approaches and Systematic Analysis of Public Microarray and RNA-Seq Datasets.Diagnostics (Basel, Switzerland) · 2019Article
- European Patent in Immunoncology: From Immunological Principles of Implantation to Cancer Treatment.International journal of molecular sciences · 2019Review
- CD4 and CD8 T lymphocyte interplay in controlling tumor growth.Cellular and molecular life sciences : CMLS · 2018Review
- Tumour-specific CD4 T cells eradicate melanoma via indirect recognition of tumour-derived antigen.Immunology and cell biology · 2016Article
- Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.Nature communications · 2016Article
- Understanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model.Frontiers in pharmacology · 2016Review
- Atypical amplification of chromosome region 22q12 in melanoma: A case report.Oncology letters · 2015Article
- Metastatic melanoma cells evade immune detection by silencing STAT1.International journal of molecular sciences · 2015Article
- Methylome analysis identifies a Wilms tumor epigenetic biomarker detectable in blood.Genome biology · 2014Article
- Construction and phenotypic analysis of mice carrying a duplication of the major histocompatibility class I (MHC-I) locus.Mammalian genome : official journal of the International Mammalian Genome Society · 2012Article
- From melanocyte to metastatic malignant melanoma.Dermatology research and practice · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 7 institutions in 2 countries.
Funding
Abstract
Abnormal expression of major histocompatibility complex (MHC) molecules in melanoma has been reported previously. However, the MHC molecule expression patterns in different growth phases of melanoma and the underlying mechanisms are not well understood. Here, we demonstrate that in vertical growth phase (VGP) melanomas, MHC genes are subject to increased rates of DNA copy number gains, accompanied by increased expression, in comparison to normal melanocytes. In contrast, MHC expression in metastatic melanomas drastically decreased compared to VGP melanomas, despite still prevalent DNA copy number gains. Subsequent investigations found that the master transactivator of MHC genes, CIITA, was also significantly downregulated in metastatic melanomas when compared to VGP melanomas. This could be one of the mechanisms accounting for the discrepancy between DNA copy number and expression level in metastatic melanomas, a potentially separate mechanism of gene regulation. These results infer a dynamic role of MHC function in melanoma progression. We propose potential mechanisms for the overexpression of MHC molecules in earlier stages of melanoma as well as for its downregulation in metastatic melanomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.